Home > Report on the risk assessment of 1-phenyl-2-(pyrrolidin-1-yl)pentan-1-one (α-pyrrolidinovalerophenone, α-PVP).

European Monitoring Centre for Drugs and Drug Addiction. [EMCDDA] (2016) Report on the risk assessment of 1-phenyl-2-(pyrrolidin-1-yl)pentan-1-one (α-pyrrolidinovalerophenone, α-PVP). Luxembourg: Publications Office of the European Union. 48 p. Risk Assessments 18

[img]
Preview
PDF (Risk assessment a-pvp)
638kB

This publication presents the data and findings of the risk assessment on α-PVP (1-phenyl- 2-(1-pyrrolidinyl)-1-pentanone), carried out by the extended Scientific Committee of the EMCDDA on 18 November 2015. α-PVP is the eleventh new psychoactive substance to be risk assessed under the terms of Council Decision 2005/387/JHA. On the basis of the Risk Assessment Report — and on the initiative of the European Commission — on 27 June 2016, the Council decided that α-PVP should be subject to control measures across the Member States.

 

Table of contents

  • Foreword
  • EMCDDA actions on monitoring and responding to new drugs
  • EMCDDA–Europol Joint Report on α-PVP: a summary
  • Risk Assessment Report of a new psychoactive substance: α-PVP
  • Annex 1: Technical report on α-PVP
  • Council Decision on subjecting α-PVP to control measures
  • Participants of the risk assessment meeting
Item Type:Evidence resource
Publication Type:Report
Drug Type:New psychoactive substance
Intervention Type:AOD disorder harm reduction
Source:EMCDDA
Date:July 2016
Pages:48 p.
Publisher:Publications Office of the European Union
Corporate Creators:European Monitoring Centre for Drugs and Drug Addiction
Place of Publication:Luxembourg
EndNote:View
Subjects:A Substance use, abuse, and dependence > Effects and consequences
B Substances > New (novel) psychoactive substances
VA Geographic area > Europe

Repository Staff Only: item control page